Cefmetazole | CAS#56796-20-4 | CAS#56796-39-5 | Cephalosporin Antibiotic

MedKoo Cat#: 317389 | Name: Cefmetazole

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Cefmetazole is a second-generation, semi-synthetic, beta-lactam cephalosporin antibiotic with antibacterial activity. Cefmetazole binds to penicillin-binding proteins (PBPs) that are responsible for crosslinking of peptidoglycan. By preventing crosslinking of peptidoglycan, cell wall integrity is lost and cell wall synthesis is halted.

Chemical Structure

Cefmetazole

CAS#56796-20-4 (free)

Theoretical Analysis

MedKoo Cat#: 317389

Name: Cefmetazole

CAS#: 56796-20-4 (free)

Chemical Formula: C15H17N7O5S3

Exact Mass: 471.0453

Molecular Weight: 471.53

Elemental Analysis: C, 38.21; H, 3.63; N, 20.79; O, 16.97; S, 20.40

Price and Availability

Size	Price	Availability
10mg	USD 350.00	2 Weeks
25mg	USD 700.00	2 Weeks
50mg	USD 1,150.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

56796-20-4 (free) 56796-39-5 (sodium)

Synonym

Cefmetazole; Cefmetazolo; Cefmetazolum; Cefmetazolum; Cefmetazolo; Sodium, Cefmetazole; U 72791A; U-72791A; U72791A; Zefazone; CS 1170; CS-1170; CS1170; Monosodium Salt, Cefmetazole; Pharmacia Brand of Cefmetazole Sodium; Salt, Cefmetazole Monosodium;

IUPAC/Chemical Name

(6R,7S)-7-[[2-(cyanomethylsulfanyl)acetyl]amino]-7-methoxy-3-[(1-methyltetrazol-5-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid

InChi Key

SNBUBQHDYVFSQF-HIFRSBDPSA-N

InChi Code

InChI=1S/C15H17N7O5S3/c1-21-14(18-19-20-21)30-6-8-5-29-13-15(27-2,17-9(23)7-28-4-3-16)12(26)22(13)10(8)11(24)25/h13H,4-7H2,1-2H3,(H,17,23)(H,24,25)/t13-,15+/m1/s1

SMILES Code

CN1C(=NN=N1)SCC2=C(N3[C@@H]([C@@](C3=O)(NC(=O)CSCC#N)OC)SC2)C(=O)O

Appearance

White to off-white solid powder.

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO, not in water

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 471.53 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Matsumura Y, Yamamoto M, Nagao M, Tanaka M, Takakura S, Ichiyama S. In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae. Diagn Microbiol Infect Dis. 2015 Dec 11. pii: S0732-8893(15)00438-1. doi: 10.1016/j.diagmicrobio.2015.12.001. [Epub ahead of print] PubMed PMID: 26782634. 2: Matsumura Y, Yamamoto M, Nagao M, Komori T, Fujita N, Hayashi A, Shimizu T, Watanabe H, Doi S, Tanaka M, Takakura S, Ichiyama S. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-β-lactamase-producing Escherichia coli bacteremia. Antimicrob Agents Chemother. 2015 Sep;59(9):5107-13. doi: 10.1128/AAC.00701-15. Epub 2015 Jun 22. PubMed PMID: 26100708; PubMed Central PMCID: PMC4538479. 3: Li LH, Yen MY, Ho CC, Wu P, Wang CC, Maurya PK, Chen PS, Chen W, Hsieh WY, Chen HW. Non-cytotoxic nanomaterials enhance antimicrobial activities of cefmetazole against multidrug-resistant Neisseria gonorrhoeae. PLoS One. 2013 May 21;8(5):e64794. doi: 10.1371/journal.pone.0064794. Print 2013. PubMed PMID: 23705013; PubMed Central PMCID: PMC3660602. 4: Doi A, Shimada T, Harada S, Iwata K, Kamiya T. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis. 2013 Mar;17(3):e159-63. doi: 10.1016/j.ijid.2012.09.010. Epub 2012 Nov 8. PubMed PMID: 23140947. 5: Akanuma S, Uchida Y, Ohtsuki S, Tachikawa M, Terasaki T, Hosoya K. Attenuation of prostaglandin E2 elimination across the mouse blood-brain barrier in lipopolysaccharide-induced inflammation and additive inhibitory effect of cefmetazole. Fluids Barriers CNS. 2011 Oct 21;8:24. doi: 10.1186/2045-8118-8-24. PubMed PMID: 22014165; PubMed Central PMCID: PMC3224590. 6: Zhang XY, Li Q, Zhou X. [The clinical efficacy and safety of intravenous cefmetazole in treatment of 1,522 patients with aspiration pneumonia]. Zhonghua Nei Ke Za Zhi. 2011 Apr;50(4):295-8. Chinese. PubMed PMID: 21600147. 7: Fukutsu N, Sakamaki Y, Kawasaki T, Saito K, Nakazawa H. Verification of cefmetazole and cefpodoxime proxetil contamination to other pharmaceuticals by liquid chromatography-tandem mass spectrometry. Chem Pharm Bull (Tokyo). 2006 Oct;54(10):1469-72. PubMed PMID: 17015995. 8: Wu TZ, Hsueh PR, Chang LY, Lu CY, Wang CY, Yang CY, Shao PL, Lee PI, Lee CY, Huang LM. Infections of cefotaxime-resistant and cefmetazole-susceptible Escherichia coli and Klebsiella pneumoniae in children. J Microbiol Immunol Infect. 2005 Apr;38(2):112-6. PubMed PMID: 15843855. 9: Abe T, Sato Y, Sei M. [Surveillance of susceptibility of clinical isolates to cefmetazole between 2000 and 2002]. Jpn J Antibiot. 2003 Dec;56(6):574-83. Japanese. PubMed PMID: 15007873. 10: Xu Y, Wang H, Chen M. [The antibacterial activity of cefmetazole and other antibiotics to 463 isolates]. Zhonghua Nei Ke Za Zhi. 1997 Aug;36(8):540-2. Chinese. PubMed PMID: 10436961. 11: Si C, Tian G. [The evaluation of cefmetazole in clinical use. The study group of cefmetazole in clinical use]. Zhonghua Nei Ke Za Zhi. 1996 Oct;35(10):668-72. Chinese. PubMed PMID: 9592326. 12: Lee DK, Wong CY, Wang DP, Chang LC, Wit KH. Stability of cefmetazole sodium and famotidine. Am J Health Syst Pharm. 1996 Feb 15;53(4):432, 442. PubMed PMID: 8673667. 13: Fracchia G, Paita L, Maglio R, Malamani T. [Occupational asthma caused by cefmetazole and 7-aminocephalosporanic acid: description of a clinical case]. G Ital Med Lav. 1996 Jan-May;18(1-3):3-5. Italian. PubMed PMID: 9312443. 14: Uete T, Matsuo K. Synergistic enhancement of in vitro antimicrobial activity of cefmetazole and cefazolin, cefotiam, cefamandole or cefoperazone in combination against methicillin-sensitive and -resistant Staphylococcus aureus. I. Effect of NaCl. Jpn J Antibiot. 1995 Apr;48(4):553-62. PubMed PMID: 7783318. 15: Wilkens B, Sullivan P, McDonald TP, Krahwinkel DJ. Effects of cephalothin, cefazolin, and cefmetazole on the hemostatic mechanism in normal dogs: implications for the surgical patient. Vet Surg. 1995 Jan-Feb;24(1):25-31. PubMed PMID: 7701767. 16: Derevianko II, Perepanova TS, Kotliarova GA, Kondrat'eva EM. [Effectiveness of cefmetazole in the treatment of infectious-inflammatory urologic diseases]. Antibiot Khimioter. 1995 Jan;40(1):37-40. Russian. PubMed PMID: 7605130. 17: Iokota T. [Problems of rational chemotherapy and the role of cefmetazole in their solution]. Antibiot Khimioter. 1995 Jan;40(1):22-6. Russian. PubMed PMID: 7605126. 18: Navashin SM. [Place of cefmetazole in modern chemotherapy]. Antibiot Khimioter. 1995 Jan;40(1):11-2. Russian. PubMed PMID: 7605124. 19: King AD, Stewart JT, Warren FW. Stability of cefmetazole-doxycycline mixtures in sodium chloride and dextrose injections. J Clin Pharm Ther. 1994 Oct;19(5):317-25. PubMed PMID: 7806603. 20: Barrientos C, González P, Tuñón MJ, Culebras JM, González-Gallego J. Effects of diabetes on disposition and hepatic handling of cefmetazole in rats. Clin Exp Pharmacol Physiol. 1993 Jun;20(6):399-404. PubMed PMID: 8339464.